Currently out of the existing stock ratings of Mani Foroohar, 109 are a BUY (53.43%), 81 are a HOLD (39.71%), 14 are a SELL (6.86%).

Mani Foroohar

Work Performance Price Targets & Ratings Chart

Analyst Mani Foroohar, carries an average stock price target met ratio of 60.06% that have a potential upside of 41.87% achieved within 223 days. Previously, Mani Foroohar worked at LEERINK.

Mani Foroohar’s has documented 363 price targets and ratings displayed on 28 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on RCKT, Rocket Pharmaceuticals at 03-Oct-2025.

Wall Street Analyst Mani Foroohar

Analyst best performing recommendations are on FDMT (4D MOLECULAR THERAPEUTICS ).
The best stock recommendation documented was for FDMT (4D MOLECULAR THERAPEUTICS ) at 11/14/2022. The price target of $15 was fulfilled within 1 day with a profit of $1.51 (11.19%) receiving and performance score of 111.93.

Average potential price target upside

of $128.86 (27.3%) on BLUE (BLUEBIRD BIO).
of $81.93 (78.38%) on ALVR (ALLOVIR ).
of $39.83 (31.16%) on MRNA (MODERNA).

ADVM Adverum Biotechnologies ALNY Alnylam Pharmaceuticals ARWR Arrowhead Pharmaceuticals BBIO BridgeBio Pharma BLUE Bluebird bio CRBU Caribou Biosciences DBTX Decibel Therapeutics DRNA Dicerna Pharmaceuticals IONS Ionis Pharmaceuticals MRNA Moderna NTLA Intellia Therapeutics RCKT Rocket Pharmaceuticals RGNX Regenxbio RXRX Recursion Pharmaceuticals WVE Wave Life Sciences Ltd SRPT Sarepta Therapeutics ABEO Abeona Therapeutics ALVR Allovir FDMT 4D Molecular Therapeutics MIRM Mirum Pharmaceuticals AMYT Amryt Pharma Holdings Ltd GRPH Graphite Bio TALS Talaris Therapeutics EDIT Editas Medicine BEAM Beam Therapeutics LXEO Lexeo Therapeutics, Common Stock NGNE Neurogene EIDX Eidos Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Matthew Caufield (HC WAINWRIGHT)